Form DFAN14A CytoDyn Inc. Filed by: Rosenbaum Paul

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 14A
(Rule 14a-101)

 

INFORMATION REQUIRED IN PROXY STATEMENT

 

SCHEDULE 14A INFORMATION

 

Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934

 

(Amendment No. )

 

Filed by the Registrant ¨

 

Filed by a Party other than the Registrant x

 

Check the appropriate box:

 

¨

Preliminary Proxy Statement

 

¨

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨

Definitive Proxy Statement

 

x

Definitive Additional Materials

 

¨

Soliciting Material Under Rule 14a-12

 

CytoDyn Inc.

(Name of Registrant as Specified in Its Charter)

 

PAUL A. ROSENBAUM
JEFFREY PAUL BEATY
ARTHUR L. WILMES
THOMAS J. ERRICO, M.D.

BRUCE PATTERSON, M.D.

PETER STAATS, M.D., MBA

MELISSA YEAGER
CCTV PROXY GROUP, LLC

(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

x

No fee required.

 

 

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
	¨	Fee paid previously with preliminary materials:

¨            Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

	(1)	Amount previously paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

 

The participants named herein (collectively, the “Participants”), have filed a definitive proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission to be used to solicit votes for the election of its slate of director nominees at the 2021 annual meeting of stockholders of CytoDyn Inc., a Delaware corporation (the “Company”).

 

   

 

On Saturday, September 18, 2021, Jeffrey Beaty, one of the Participants, sent the following email inviting certain stockholders of the Company to attend a Zoom webinar:

 

Dear Stockholder,

 

You are cordially invited to attend a Zoom webinar being co-moderated by Jeff Kight and Jeff Beaty.  Paul Rosenbaum, Art Wilmes, Dr. Bruce Patterson, Dr. Thomas Errico, Dr. Peter Staats, and Melissa Yeager will discuss their Long Hauler plans including trial design and financial impact for the company, proper BLA submission protocol, and potential government funding.  

 

Please note that participation will be limited to 500 attendees and we encourage you to register in advance. 

 

Questions should be submitted in advance to [email protected].

 

WHEN: The webinar will be held on Tuesday, September 21, 2021 at 7:30 p.m. Eastern Daylight Time.

 

Register in advance for this webinar:
https://us02web.zoom.us/webinar/register/WN_E54HlMWxRk63bkq_Nu8S4Q

After registering, you will receive a confirmation email containing information about joining the webinar.

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ACTS LAW Addresses Federal Correctional Institution in Dublin Controversy
• Amteck Graduates Seven Apprentices
• ESSA Bancorp, Inc. Announces Fiscal Second Quarter and Fiscal First Half 2024 Financial Results